11,838 Shares in Becton, Dickinson and Company (NYSE:BDX) Purchased by Edgestream Partners L.P.

Edgestream Partners L.P. bought a new stake in Becton, Dickinson and Company (NYSE:BDX) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 11,838 shares of the medical instruments supplier’s stock, valued at approximately $2,767,000.

Several other institutional investors also recently added to or reduced their stakes in the business. WR Wealth Planners LLC increased its position in Becton, Dickinson and Company by 1.4% during the second quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock worth $696,000 after acquiring an additional 42 shares during the period. Ridgewood Investments LLC grew its position in Becton, Dickinson and Company by 1.5% in the 1st quarter. Ridgewood Investments LLC now owns 2,956 shares of the medical instruments supplier’s stock worth $731,000 after purchasing an additional 43 shares during the last quarter. Key Client Fiduciary Advisors LLC increased its holdings in shares of Becton, Dickinson and Company by 2.6% during the 1st quarter. Key Client Fiduciary Advisors LLC now owns 1,715 shares of the medical instruments supplier’s stock worth $424,000 after purchasing an additional 43 shares during the period. Clear Creek Financial Management LLC raised its position in shares of Becton, Dickinson and Company by 5.1% during the second quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock valued at $210,000 after buying an additional 44 shares during the last quarter. Finally, Edge Capital Group LLC lifted its stake in shares of Becton, Dickinson and Company by 3.1% in the fourth quarter. Edge Capital Group LLC now owns 1,573 shares of the medical instruments supplier’s stock valued at $384,000 after buying an additional 48 shares during the period. 86.97% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Raymond James cut their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Stifel Nicolaus boosted their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. Evercore ISI reduced their price objective on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. Finally, The Goldman Sachs Group assumed coverage on shares of Becton, Dickinson and Company in a research note on Thursday, May 30th. They issued a “buy” rating and a $274.00 target price on the stock. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, Becton, Dickinson and Company presently has an average rating of “Moderate Buy” and an average price target of $279.50.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock opened at $231.58 on Thursday. The stock has a market capitalization of $66.93 billion, a price-to-earnings ratio of 51.01, a P/E/G ratio of 1.91 and a beta of 0.42. The firm’s 50-day moving average price is $235.23 and its two-hundred day moving average price is $235.54. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $269.52.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. The firm had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The business’s revenue was up 2.3% on a year-over-year basis. During the same period last year, the firm posted $2.96 EPS. On average, equities analysts predict that Becton, Dickinson and Company will post 13.1 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be issued a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a yield of 1.64%. The ex-dividend date is Monday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 83.70%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.